Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion
TAS6417-301
Phase 3 small_molecule active
Quick answer
Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion for Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations is a Phase 3 program (small_molecule) at Taiho Pharma Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Taiho Pharma Netherlands B.V.
- Indication
- Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active